Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Roger S. Newton, Ph.D., Esperion’s executive chairman, chief scientific officer and company founder, will present at the Stifel Nicolaus 2013 Healthcare Conference in Boston. Dr. Newton’s presentation will take place on Wednesday, September 11, at 3:50 p.m. ET at the Four Seasons Hotel.
To hear the live audio webcast and view the slides of the Esperion presentation, please visit http://www.veracast.com/webcasts/stifel/healthcare2013/28113409462.cfm. A replay of the webcast will be available on the company’s website for 30 days following the live event.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on the research, development and commercialization of therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (LDL-C) and other cardiometabolic risk factors. ETC-1002, Esperion’s lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. ETC-1002 is targeted for statin intolerant patients with elevated levels of LDL-C. Esperion has completed seven clinical studies to date, including four Phase 2a studies, and expects to initiate a robust Phase 2b clinical program in the fourth quarter of 2013. For more information, please visit www.esperion.com.
Denise Powell, 510-703-9491
|Amicus Therapeutics to Present at Stifel Nicolaus 2013 Healthcare Conference (2013/9/5)|
|GTx Announces Webcast of Corporate Presentation at Stifel Nicolaus 2013 Healthcare Conference (2013/9/6)|
|Acorda Therapeutics to Present at the Stifel Nicolaus 2013 Healthcare Conference (2013/9/5)|
|Vanda Pharmaceuticals to Present at the Stifel Nicolaus 2013 Healthcare Conference (2013/9/10)|
|Idera to Present at the Stifel Nicolaus 2013 Healthcare Conference (2013/9/10)|
|OvaScience to Present at the Stifel Nicolaus 2013 Healthcare Conference (2013/9/6)|
|MAXIMUS to Present at the Stifel Nicolaus 2013 Healthcare Conference on September 11 (2013/9/9)|
|Endo Health Solutions to Present at the Stifel Nicolaus 2013 Healthcare Conference (2013/9/6)|
|AngioDynamics to Present at the Stifel Nicolaus 2013 Healthcare Conference (2013/8/28)|
|The Ensign Group to Present at the Stifel Nicolaus 2013 Healthcare Conference on September 11, 2013 (2013/9/6)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.